# Junta clínica — PT-pseudo_dd011d696387 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_dd011d696387",
  "pid": "PT-pseudo_dd011d696387",
  "task": 1,
  "psa": 10.0,
  "age": 75,
  "months": 3,
  "pirads": "5",
  "psad": 0.372,
  "psav": 0.55,
  "psap": 14.0,
  "vol": 26.91,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8577571,
  "medhx": "Coronary artery disease, Benign prostatic hyperplasia",
  "meds": "atorvastatin, tamsulosin",
  "notes": "PSA 10 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 27 mL. csPCa 0.86.",
  "pmhx": [
    "Coronary artery disease",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "92 kg",
    "height": "179 cm",
    "bmi": "28.7",
    "bp": "101/75 mmHg",
    "hr": "73 bpm",
    "smoking": "Ex-smoker (13 pack-yr, quit 2002)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "11 Jan 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical attention sought for reassessment of a previously confirmed prostate malignancy alongside recent fluctuations in prostate-specific antigen levels."
    },
    {
      "s": "History",
      "t": "Clinical review initiated to reassess a previously established prostate cancer diagnosis. At 75 years of age, he works as an active dairy farmer and resides independently as a widower, relying on his adult daughter as his main point of contact. Body mass indexes 28.7 at a weight of 92 kg. Tobacco use ceased in 2002, accounting for a cumulative 13 pack-year exposure. Chronic coronary artery disease remains controlled via atorvastatin, while tamsulosin addresses benign prostatic hyperplasia; lower urinary tract symptoms are negligible, scoring just 2 on the IPSS scale. Daily life centers around agricultural work, with otherwise limited physical activity. Alcohol intake stays around three units weekly. Public transit limitations dictate a preference for morning visits. A decades-old meniscal injury occasionally flares during wet conditions, and he maintains routine cardiology appointments solely for blood pressure tracking. Unexplained weight reduction, skeletal discomfort, and blood in the urine are firmly denied, as he prioritizes continuing his agricultural schedule. December 2024 bloodwork revealed a prostate-specific antigen level of 10.0 ng/mL (free fraction 16%), complemented by unremarkable renal panels and complete blood counts. No medication sensitivities exist."
    },
    {
      "s": "Physical examination",
      "t": "Digital rectal examination proves normal; the prostate presents as symmetrically enlarged with a smooth, firm consistency and absent nodules or asymmetry. Hemodynamic parameters show a blood pressure of 101/75 mmHg and a pulse of 73 beats per minute. Systemic assessment identifies a well-nourished individual exhibiting no signs of acute distress; pulmonary fields are clear and cardiac rhythm remains regular."
    }
  ],
  "occupation": "active dairy farmer",
  "marital": "Widowed",
  "living": "Lives alone; adult daughter is primary contact",
  "next_of_kin": "None recorded — patient declines to nominate",
  "recent_other": [],
  "alcohol": "3 units / week",
  "exercise": "Sedentary lifestyle, occasional walking",
  "ipss": "IPSS score: 2/35 (mild LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "UMCG (Groningen)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_dd011d696387
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 75-year-old male
  - PSA: 10.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.372 ng/mL²
  - PSA velocity: 0.55 ng/mL/yr
  - Prior PSA: 14.0 ng/mL
  - Prostate volume: 26.91 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8577571 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Coronary artery disease, Benign prostatic hyperplasia
  - Problem list / PMHx: Coronary artery disease, Benign prostatic hyperplasia
  - Current medication: atorvastatin, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 10 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 27 mL. csPCa 0.86.

Vitals: weight 92 kg, height 179 cm, BMI 28.7, BP 101/75 mmHg, HR 73 bpm. Smoking: Ex-smoker (13 pack-yr, quit 2002).

Chief complaint: Clinical attention sought for reassessment of a previously confirmed prostate malignancy alongside recent fluctuations in prostate-specific antigen levels.

History: Clinical review initiated to reassess a previously established prostate cancer diagnosis. At 75 years of age, he works as an active dairy farmer and resides independently as a widower, relying on his adult daughter as his main point of contact. Body mass indexes 28.7 at a weight of 92 kg. Tobacco use ceased in 2002, accounting for a cumulative 13 pack-year exposure. Chronic coronary artery disease remains controlled via atorvastatin, while tamsulosin addresses benign prostatic hyperplasia; lower urinary tract symptoms are negligible, scoring just 2 on the IPSS scale. Daily life centers around agricultural work, with otherwise limited physical activity. Alcohol intake stays around three units weekly. Public transit limitations dictate a preference for morning visits. A decades-old meniscal injury occasionally flares during wet conditions, and he maintains routine cardiology appointments solely for blood pressure tracking. Unexplained weight reduction, skeletal discomfort, and blood in the urine are firmly denied, as he prioritizes continuing his agricultural schedule. December 2024 bloodwork revealed a prostate-specific antigen level of 10.0 ng/mL (free fraction 16%), complemented by unremarkable renal panels and complete blood counts. No medication sensitivities exist.

Physical examination: Digital rectal examination proves normal; the prostate presents as symmetrically enlarged with a smooth, firm consistency and absent nodules or asymmetry. Hemodynamic parameters show a blood pressure of 101/75 mmHg and a pulse of 73 beats per minute. Systemic assessment identifies a well-nourished individual exhibiting no signs of acute distress; pulmonary fields are clear and cardiac rhythm remains regular.

Patient info: active dairy farmer; Widowed; Lives alone; adult daughter is primary contact.
Next of kin: None recorded — patient declines to nominate.

Lifestyle: alcohol 3 units / week; exercise Sedentary lifestyle, occasional walking; IPSS score: 2/35 (mild LUTS).


Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.61
  uncertainty  +/- 0.12 (95% CI 0.37-0.85); among patients it cannot tell apart the outcome was 0.96 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using a risk-based pathway based on PI-RADS score and PSA density to guide biopsy decisions. It states that patients with a PI-RADS score of 1-3 and a low-risk profile (PSA-D < 0.15ng/mL/cc, negative DRE, no family history, no ASAP or ISUP1 cancer at prior biopsy) could forgo biopsy.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's bid of BIOPSY is not settled because it fails to account for the guideline's risk-based stratification variables. Specifically, the classifier did not adequately weigh the threshold for PSA density (0.15 ng/mL/cc) or the PI-RADS score (1-3) that the guideline uses to suggest avoiding biopsy.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose shows a PI-RADS score of 5, which is high risk, which suggests a biopsy according to the guideline's general trigger.
PSA density - The PSA density is 0.372 ng/mL², which is significantly above the guideline's threshold of 0.15 ng/mL/cc, which suggests a higher risk profile.
Prior biopsy status - The prior biopsy status is 'Positive', which is a critical factor that the guideline uses to determine the subsequent management pathway.
Prostate volume - The prostate volume is 26.91 mL, which is a known variable in risk stratification that the guideline uses to assess the overall risk.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on reconciling the high-risk imaging features with the prior positive biopsy result, which the guideline suggests requires further stratification.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine the mpMRI prose, specifically focusing on lesion size, zone, and extraprostatic extension.
  psa_trend (get_psa_trend) -> Determine the serial PSA values to assess the PSA velocity and trend.
  previous_notes (get_previous_notes) -> Review the management context, including what was agreed upon following the prior positive biopsy.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Does the mpMRI prose confirm the PI-RADS 5 finding and provide any information regarding extraprostatic extension?
  Q2. What is the PSA trend over time, and does this information help stratify the risk beyond the established variables?

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose confirms the PI-RADS 5 finding, describing a discrete hypointense focus in the left peripheral zone measuring approximately 14 mm, with high diffusion restriction.
psa_trend
The serial PSA values are: Nov 2023: 2.9 ng/mL, Mar 2024: 1.2 ng/mL, Jun 2024: 4.6 ng/mL, Sep 2024: 8.7 ng/mL, and Jan 2025: 10.0 ng/mL.
previous_notes
The previous notes indicate that a urology consultation was arranged in July 2023 to investigate the ongoing marker elevation alongside earlier positive biopsy results.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not explicitly ask for it, and the key metrics (PSA density, PI-RADS) were already present in the structured panel.

WHAT THIS SUPPORTS
FOR sampling this patient now
mpMRI report shows a PI-RADS 5 lesion and high diffusion restriction.
PSA trend shows a clear upward trajectory, with the most recent value being 10.0 ng/mL.
AGAINST sampling this patient now
Prior biopsy status is 'Positive', which is a critical factor in the cohort data.

WHERE THIS LEANS
The high-risk imaging features and the rising PSA trend strongly suggest a need for further tissue characterization, despite the prior positive biopsy.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar answered Q1 by stating the mpMRI report confirms the PI-RADS 5 finding and describes a 14 mm lesion with high diffusion restriction. The registrar did not provide information regarding extraprostatic extension.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-CLASSIFIER's suggestion of BIOPSY because the mpMRI report shows a PI-RADS 5 lesion, and the PSA trend shows a clear upward trajectory, both of which support further tissue characterization.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the mpMRI prose confirm the PI-RADS 5 finding and provide any information regarding extraprostatic extension? Answered by REGISTRAR with the finding that the mpMRI report confirms the PI-RADS 5 finding and describes a 14 mm lesion with high diffusion restriction.
Q2. What is the PSA trend over time, and does this information help stratify the risk beyond the established variables? Answered by REGISTRAR with the serial PSA values showing a clear upward trajectory, which supports the need for further tissue characterization.

WHAT CARRIES WEIGHT, AND WHY
The variables that matter most are the PI-RADS score because it indicates high-risk imaging features, the PSA trend because it shows a clear upward trajectory, and the prior biopsy status because it is a critical factor in the cohort data. The guideline does not explicitly support deferral when PI-RADS is 5 and PSA is rising, as these are high-risk indicators. The guideline does not support the cohort's finding that prior biopsy status overrides these imaging/trend factors.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy to further characterize the high-risk lesion and the rising PSA trend, despite the prior positive biopsy. This should be done with a focus on targeted sampling based on the imaging findings.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

Given the patient already has a prior positive biopsy, and the retrieved documents do not provide a specific finding that would alter the management pathway, deferral is appropriate. The high PI-RADS 5 and rising PSA trend are expected in a known cancer, and there is no documented finding that necessitates re-sampling to change the established treatment plan.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
